Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
Bicara Therapeutics director and Chief Executive Officer Claire Mazumdar reported a series of option exercises and related share sales. Over March 4–6, 2026, she exercised stock options to acquire a total of 8,234 shares of common stock at an exercise price of
On each day, the same number of shares was sold in open‑market transactions, totaling 8,234 shares sold at weighted average prices around
BCAX filed a Form 144 reporting the planned sale of 3,817 common shares by the issuer through the exercise of stock options for cash on 03/06/2026. The filing also discloses prior sales by Claire Mazumdar: 2,631 shares (03/04/2026) and 1,786 shares (03/05/2026) with dollar amounts listed.
Bicara Therapeutics director and President/COO Ryan Cohlhepp exercised stock options and sold shares of the company on March 3, 2026. He exercised options for 12,892 shares of common stock and then sold a total of 17,392 shares in open-market transactions.
The sales, executed under a Rule 10b5-1 trading plan adopted on February 12, 2025, occurred at a weighted average price of $18.1631 per share, with individual trades ranging from $18.00 to $18.32. After these transactions, he directly held 205,141 shares of Bicara common stock.
Bicara Therapeutics Chief Financial Officer Hyep Ivan reported option exercises and share sales in early March 2026. On March 3–4, he exercised stock options to acquire a total of 16,518 shares of common stock at a reported exercise price of
After these transactions, he directly owned 145,355 shares of Bicara common stock and held stock options covering 79,784 shares, subject to vesting in equal quarterly installments following April 5, 2023 and August 8, 2023, contingent on his continued service.
Bicara Therapeutics Chief Medical Officer David Raben reported a series of option exercises and related stock sales in early
On the same dates, he sold 16,500 shares of Bicara Therapeutics Inc. common stock in open-market transactions at prices including
Claire Mazumdar files a Form 144 reporting a proposed sale of common stock of UBS Financial Services, Inc., listing 1,786 shares to be sold on 03/05/2026 via exercise of stock options for cash. The filing separately records that 2,631 shares were sold on 03/04/2026 for $49,288.63.
BCAX issuer files a Form 144 proposing the sale of 2,963 common shares. The sale is listed as an exercise of stock options by the issuer for cash with an effective date of 03/04/2026.
The filing also lists past sales by Ivan Hyep: 9,200 shares on 12/22/2025, 1,882 shares on 01/22/2026, and 13,555 shares on 03/03/2026, with the dollar proceeds shown for each sale.
BCAX reports the sale of 16,300 shares of common stock under Rule 144, associated with the exercise of stock options and processed through UBS Financial Services on
Separately, the filing shows a prior sale of 200 shares by David Raben on
BCAX submitted a Form 144 reporting a proposed sale of 13,555 common shares to be sold on
The filing also discloses prior sales by the reporting person: 9,200 shares on